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Abstract
Background: Systemic sclerosis (SSc) is a genetically complex autoimmune disease mediated by the interplay
between genetic and epigenetic factors in a multitude of immune cells, with CD4+ T lymphocytes as one of the
principle drivers of pathogenesis.
Methods: DNA samples exacted from CD4+ T cells of 48 SSc patients and 16 healthy controls were hybridized on
MethylationEPIC BeadChip array. In parallel, gene expression was interrogated by hybridizing total RNA on Clariom™
S array. Downstream bioinformatics analyses were performed to identify correlating differentially methylated CpG
positions (DMPs) and differentially expressed genes (DEGs), which were then confirmed utilizing previously
published promoter capture Hi-C (PCHi-C) data.
Results: We identified 9112 and 3929 DMPs and DEGs, respectively. These DMPs and DEGs are enriched in
functional categories related to inflammation and T cell biology. Furthermore, correlation analysis identified 17,500
possible DMP-DEG interaction pairs within a window of 5 Mb, and utilizing PCHi-C data, we observed that 212
CD4+ T cell-specific pairs of DMP-DEG also formed part of three-dimensional promoter-enhancer networks,
potentially involving CTCF. Finally, combining PCHi-C data with SSc GWAS data, we identified four important SSc-
associated susceptibility loci, TNIP1 (rs3792783), GSDMB (rs9303277), IL12RB1 (rs2305743), and CSK (rs1378942), that
could potentially interact with DMP-DEG pairs cg17239269-ANXA6, cg19458020-CCR7, cg10808810-JUND, and
cg11062629-ULK3, respectively.
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Conclusion: Our study unveils a potential link between genetic, epigenetic, and transcriptional deregulation in
CD4+ T cells of SSc patients, providing a novel integrated view of molecular components driving SSc pathogenesis.
Keywords: Systemic sclerosis, DNA methylation, Epigenetics, Long-distance regulation, Hi-C, Genetic susceptibility
variants, CTCF
Background
Systemic sclerosis (SSc) is a chronic, progressive auto-
immune disease of unknown etiology that is primarily
characterized by extensive microvascular damage, de-
regulation of immune cells, and systemic fibrosis of the
skin and various organs. The estimated overall 10-year
survival rate is 66%, which significantly decreases upon
organ involvement [1]. SSc patients can be broadly cate-
gorized into three groups based on the extent of skin in-
volvement: those with restricted involvement affecting
the limbs distal to the elbows or knees with or without
face and neck involvement are classified as limited cuta-
neous SSc (lcSSc) or those with proximal involvement
affecting above the elbows and knees are classified as
diffuse cutaneous SSc (dcSSc) and sine scleroderma with
Raynaud’s phenomenon, visceral involvement, and auto-
antibodies but no skin involvement [2]. A proposed clas-
sification by the Royal Free Hospital in 1996, currently
used by Spanish Scleroderma Registry (RESCLE), in-
cluded early (eSSc) and very early scleroderma [3, 4].
The pathogenesis of SSc is not well-understood, in
which disease onset and development appear to be mul-
tistep and multifactorial processes involving both genetic
and environmental factors [5, 6].
Like most autoimmune diseases, genetics studies have
revealed that SSc heritability is complex with the HLA
loci playing an important contribution to disease risk
[7]. Recent genome-wide association (GWAS) and
immunochip array SNP studies revealed the presence of
numerous non-HLA loci that associate with disease on-
set, including genes of type I interferon pathway,
interleukin-12 pathway, and TNF pathway as well as B
and T cell-specific genes [8–14]. Furthermore, recent
chromatin interaction analyses have linked these genetic
variants to potential target genes implicated in SSc dis-
ease progression [15]. However, genetic variants do not
account for all of the genetic burden of SSc, where other
factors, such as epigenetic dysregulation, play an indis-
pensable role in disease pathogenesis [5, 16].
It is well-established that CD4+ T cells play a pivotal
role in the pathogenesis of several autoimmune diseases.
Abnormalities in the proportions of CD4+ T lymphocyte
subpopulations were detected more than two decades ago
in SSc patients [17, 18], and since then, several studies
proposed mechanistic alterations in these lymphocyte
populations that may contribute to disease manifestations.
Firstly, increased production of several CD4+ T cell-
mediated cytokines, including IL-27, IL-6, TGF-β, and IL-
17A, was detected in the serum of SSc patients, which
may directly drive vascular dysregulation and fibrosis [19,
20]. Secondly, CD4+ T cells isolated from SSc patients
were observed to be functionally impaired, as stimulation
resulted in deregulated polarization towards Th17 expan-
sion, as well as inherent diminished immune capacity of
circulating Treg cells [21, 22]. Finally, aberrant interac-
tions with other cell types, including mesenchymal stro-
mal cells and fibroblasts, have been observed [23, 24]. The
exact mechanism that drives CD4+ T cell deregulation in
SSc is currently unknown; however, there is strong evi-
dence that alterations in DNA methylation may be a
primary culprit. DNA methylation plays a critical role in T
cell polarization and activation, in which naïve T cells
undergo reprograming of its methylome to increase acces-
sibility of selective loci upon differentiation into different
T helper lymphocyte subpopulations (reviewed in [25,
26]). Gene expression of DNA methylation-related pro-
teins were observed to be deregulated in SSc [27]. Several
studies have observed aberrant methylation of promoters
of such genes as CD40L [28], TNFSF7 [29], FOXP3 [30],
and IFN-associated genes [31], which may result in their
aberrant expression.
In this study, we describe the relationship between DNA
methylation and gene expression in SSc CD4+ T cells, and
how aberrant DNA methylation potentially deregulates
the expression of several important inflammatory genes
through long-distance enhancer-promoter interactions.
Furthermore, these alterations appear to correlate with
the presence of genetic variants in nearby loci.
Methods
Patient cohort and CD4+ T cell isolation
This study included 48 SSc patients and 16 age- and sex-
matched healthy donors (HD). Individuals included in this
study gave both written and oral consent in regard to the
possibility that donated blood would be used for research
purposes. Samples were collected at Vall d’Hebron Hos-
pital, Barcelona, in accordance with the ethical guidelines
of the 1975 Declaration of Helsinki. The Committee for
Human Subjects of the Vall d’Hebron Hospital and Bell-
vitge Hospital approved the study. Patients with SSc who
fulfilled the 2013 American College of Rheumatology/
European League Against Rheumatism (ACR/EULAR)
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criteria or the modified criteria proposed by LeRoy
and Medsger in 1988 were included [32, 33]. Four
clinical subsets were considered: diffuse SSc, limited
SSc, sine SSc, and early SSc (patients who met the
criteria for very early disease and also presented in-
cipient visceral involvement or other manifestations
(digital ulcers (DU) or pitting scars, telangiectasia,
calcinosis, or arthritis)) [4]. Characteristics of patient
cohort are summarized in Additional file 1: Table S1.
CD4+ T lymphocyte population was isolated from whole
blood by fluorescence-activated cell sorting performed at
the Unitat de Biologia (Campus de Bellvitge), Centres Cien-
tífics i Tecnològics, Universitat de Barcelona (Spain).
Briefly, peripheral blood mononuclear cells (PBMCs) were
separated by laying on Lymphocytes Isolation Solution
(Rafer, Zaragoza, Spain) and centrifuged without braking.
PBMCs were stained with fluorochrom-conjugated anti-
body against CD4-APC (BD Pharmingen, New Jersey,
USA) in staining buffer (PBS with 2mM of EDTA and 4%
FBS) for 20 min. Gating strategies were employed to elim-
inate doublets, cell debris, and DAPI+ cells. Lymphocytes
were separated by forward and side scatter, in which CD4+
cells were separated by positive selection.
RNA/DNA isolation
RNA and DNA were isolated from the same cell pellet
utilizing AllPrep DNA/RNA/miRNA Universal Kit
(Qiagen, Hilden, Germany) according to manufacturer’s
instructions. RNA quality was assessed by the 2100
Bioanalyzer System (Agilent, CA, USA) carried out at
the High Technology Unit (UAT), at Vall d’Hebron
Research Institute (VHIR).
Illumina EPIC methylation assay and data processing
Bisulfite (BS) conversion was performed using EZ-96
DNA Methylation™ Kit (Zymo Research, CA, USA) ac-
cording to manufacturer’s instructions. Five hundred
nanograms of BS-converted DNA was hybridized on
Infinium MethylationEPIC Bead Chip array (Illumina,
Inc., San Diego, CA, USA) following manufacturer’s in-
structions to assess DNA methylation of 850,000 se-
lected CpGs that cover 99% of annotated RefSeq genes.
Fluorescence of probes was detected by BeadArray
Reader (Illumina, Inc.), and image processing and data
extraction were performed as previously described [34].
Downstream data processing and normalization were per-
formed using the R statistical language. Probes were first
filtered by detection p value (p < 0.01) and normalized by
Illumina normalization provided by the minfi package.
CpGs in single nucleotide polymorphism loci were elimi-
nated. An additional filter of beta values (ratio of DNA
methylation) was applied, in which top 5% of CpGs with
the highest Δbeta between sample groups were retained
for further analyses. ComBat adjustment, provided by the
sva package, was performed to remove bias from batches.
M values (log2-transformed beta values) were utilized to
obtain p value and adjusted p value (Benjamini-Hochberg-
calculated FDR) between sample groups by an eBayes-
moderated paired t test using the limma package [35]. p
value of < 0.01 and FDR of < 0.05 were considered statisti-
cally significant. Differentially methylated regions (DMRs)
were identified using the bumphunter function from
minfi, in which a p value of < 0.05 and a region containing
2 or more CpGs were considered DMRs. Raw DNA
methylation dataset is available at GEO with accession
number GSE146093 [36].
Clariom S gene expression array and data processing
One hundred nanograms of excellent quality RNA (RNA
integrity number of > 9) was hybridized on Clariom™ S
array, carried out at the High Technology Unit (UAT),
at Vall d’Hebron Research Institute (VHIR), which inter-
rogates the expression of > 20,000 transcripts. Data pro-
cessing and normalization were carried out using the R
statistical language. Background correction was per-
formed using Robust Microarray Analysis (RMA)
normalization provided by oligo package [37]. Annota-
tion of probes was performed using clariomshumantran-
scriptcluster.db package [38], and the average expression
level was calculated for probes mapped to the same
gene. ComBat adjustment, provided by the sva package,
was performed to remove bias from batches and other
confounding variables. For comparisons between groups,
the limma package was used to perform an eBayes-
moderated paired t test provided in order to obtain log2
fold change (log2FC), p value, and adjusted p value
(Benjamini-Hochberg-calculated FDR). Genes that dis-
played statistically significant tests (p value < 0.01 and
FDR < 0.05) were considered differentially expressed.
Deconvolution analysis was performed using the ABsolute
Immune Signal (ABIS) deconvolution online tool [39].
Raw gene expression dataset is available at GEO with
accession number GSE146093 [36].
Gene ontology, motif, and regulon enrichment analyses
Gene ontology (GO) analysis of differentially methylated
CpG positions (DMPs) and regions (DMRs) was per-
formed using the GREAT online tool ((http://great.stan-
ford.edu/public/html) [40], in which genomic regions
were annotated by applying the basal plus extension set-
tings. For DMPs, annotated CpGs in the EPIC array
were used as background, and for DMRs, default back-
ground was used. GO terms with p value < 0.01 and fold
change (FC) > 2 were considered significantly enriched.
GO analysis of differentially expressed genes (DEGs) was
carried out using the online tool DAVID (https://david.
ncifcrf.gov) under Functional Annotation settings, in
which annotated genes in the Clariom™ S array were
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used as background. GO categories with p value of
< 0.01 were considered significantly enriched.
Motif enrichment analysis of DMPs was performed
using the findMotifsGenome.pl tool provided by the
HOMER motif discovery software [41]. A window of ±
250 bp surrounding each DMP was applied, and CpGs
annotated in the EPIC array were used as background.
Transcription factor (TF) enrichment of DEGs was car-
ried out using the DoRothEA (Discriminant Regulon Ex-
pression Analysis) v2 tool [42]. Regulons with
confidence score of A–C were utilized for analysis, and a
p value of < 0.05 and normalized enrichment score
(NES) of ± 2 were considered significantly enriched.
Comparative analysis with public ChIP-seq datasets
DNase I hypersensitivity and ChIP-seq data of histone
modifications H3K27ac, H3K4me1, H3K4me3, H3K27me3,
H3K36me3, and H3K9me3 of total CD4+ T cells were
downloaded from the BLUEPRINT portal (http://dcc.blue-
print-epigenome.eu/) [43]. Five independent datasets were
downloaded for each histone mark, and ChIP-seq peaks
were consolidated using the MSPC program [44], in which
peaks were first filtered by q value < 0.01 and FC ≥ 2 and
using the parameters -w = 1E-4, -s =1E-8, and -c = 3.
ChIP-seq datasets of transcription factors were down-
loaded from ReMap database (http://pedagogix-tagc.
univ-mrs.fr/remap) [45]. ChIP-seq data of STAT1,
RUNX1, NFKB2, MYC, JUN, CTCFL, and CTCF were
downloaded as merged peaks of all available data,
whereas RELA data was generated in CD4+ T cells.
Background of DMRs was generated from annotated
CpGs from EPIC array by randomly permutating 1000
times, and an average p value of < 0.01 and average odds
ratio > 1 were considered significantly enriched.
Methylation-expression quantitative trait loci and
promoter capture Hi-C data analyses
Methylation-expression quantitative trait loci (meQTL)
analysis to link varying gene expression to aberrant DNA
methylation was carried out utilizing the MatrixEQTL
package, including sex and age as covariates [46]. A win-
dow of 5Mb was applied for cis interactions, and a
Pearson correlation p value of < 0.01 was considered sig-
nificant. CpG-gene interactions were then filtered by
differential methylation and expression in SSc T cells
compared to controls (FDR < 0.05 and p value < 0.01).
Promoter capture Hi-C (PCHi-C) datasets were gener-
ated previously in naïve, non-activated, and activated
CD4+ T cells from healthy controls [47]. Briefly, cells
are fixed by paraformaldehyde, lysed, and subjected to
Hind III digestion. Restriction fragments (median size of
5 kb) were then biotinylated, and interacting fragments
were ligased. "Captured fragments were then used to
generate Hi-C libraries where fragments were mapped to
either a gene promoter or intergenic region [48]. Utiliz-
ing significant PCHi-C interactions, we first performed
overlap between DEGs and mapped promoters from
PCHi-C datasets. Second, we utilized pipelines provided
by GenomicRanges package [49] to overlap the interact-
ing PCHi-C fragments with DMP coordinates. Finally,
we eliminated the DMPs found in gene promoters, in
which 212 unique DMP-DEG interactions remained.
Confirmed interactions were visualized using WashU
Epigenome Browser (http://epigenomegateway.wustl.
edu/legacy).
Association analysis and genotyping of risk variants
Genome-wide association study (GWAS) data was ob-
tained from López-Isac et al. [15], in which SSc-
associated susceptibility loci and their interacting genes
were overlapped, by gene name, with DMP-DEG pairs
identified from this study. Genome-wide genotyping was
performed utilizing purified DNA obtained from periph-
eral blood mononuclear cells of our cohort of 48 SSc pa-
tients using standard methods and hybridized on
Illumina GWAS platforms (HumanCytoSNP-12v2 and
Illumina HumanCore) according to the manufacturer’s
instructions. Stringent quality controls were applied
using PLINK [50]. Detailed information is described in
López-Isac et al. [15].
Results
DNA methylation deregulation in SSc CD4 T cells
To gain insights into functional and molecular alter-
ations of T lymphocytes in the context of SSc pathogen-
esis, we first isolated CD4+ T lymphocytes from the
PBMCs of 48 SSc patients and 16 age- and sex-matched
healthy donors (HD) by CD4+ positive cell sorting
(Fig. 1a, b; Additional file 1: Table S1). To interrogate
DNA methylation, we utilized bead arrays (see the
“Methods” section). Subsequently, 9112 CpGs were
found to be differentially methylated in SSc CD4+ T
cells compared to HD (FDR < 0.05 and p value < 0.01),
in which 7837 and 1275 CpGs were hyper- and hypo-
methylated, respectively (Fig. 1c; Additional file 2: Table
S2). Analysis of differentially methylated CpG positions
(DMPs) was visualized by t-distributed stochastic neigh-
bor embedding (t-SNE) analysis (Fig. 1d), and HD and
SSc samples can be observed to separate along the t-
SNE2 axis. DMPs were predominantly situated in open
sea and intergenic regions (Additional file 3: Fig. S1A).
Gene ontology analysis revealed relevant categories for
both hyper- and hypomethylated DMPs (Fig. 1e). Hyper-
methylated DMPs were enriched in inflammatory path-
ways, including IL-23 and IL-18 receptor activity and
TLR3 signaling pathway, as well as pathways involved in
T cell biology, such as memory and Th17 T cell differen-
tiation (Fig. 1e, upper panel; Additional file 4: Table S3).
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Fig. 1 (See legend on next page.)
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On the other hand, hypomethylated DMPs were pre-
dominantly enriched in genes encoding the MHC pro-
tein complex (Fig. 1e, lower panel; Additional file 3: Fig.
S1B; Additional file 4: Table S3). Other relevant categor-
ies, including proliferation, Th1-type immune response,
and IL-10 production, were also enriched in hypomethy-
lated DMPs. Motif enrichment analyses revealed zinc
finger transcription factor CTCF to be common to both
hyper- and hypomethylated DMPs (Fig. 1f). This obser-
vation is especially interesting given the importance of
CTCF in mediating enhancer-gene interactions [51];
hence, aberrant DNA methylation of CTCF binding en-
hancer regions may affect the expression of interacting
genes. Furthermore, other motifs of TF complexes im-
portant to T cell biology, such as the BAFT-JUN-AP1
complex, shown to play a role in CD4+ T cell differenti-
ation [52], and TFs of the ETS family, whose deletion in
CD4+ T cells result in autoimmunity in mice [53], were
enriched in the hypomethylated cluster (Fig. 1f). Subse-
quent analyses revealed that hypermethylated DMPs
showed a particular histone mark signature that was
enriched in H3K9me3, H3K27me3, and H3K4me1
(Fig. 1g), which suggest the enrichment of poised en-
hancers, as was previously defined by Zentner et al. [54].
Conversely, hypomethylated DMPs were significantly
enriched in H3K4me1 only, which is a hallmark of
primed enhancers (Fig. 1g) [55]. Finally, among the
DNA methylation alterations detected in SSc patients,
we also observed 852 CpGs that changed their variance
compared to healthy controls, and these are termed dif-
ferentially variable positions (DVPs; Fig. 1h). Many of
these CpGs were also differentially methylated; however,
453 CpGs were exclusively DVPs, and majority of them
experienced an increase in variance in SSc patients
(Fig. 1h). Increases in variance may be a consequence of
differences in pathological evolution of the disease in the
patient population. Overall, deregulation in DNA methy-
lation of genes important to immune response and T
cell biology was detected in peripheral blood-isolated
CD4+ T cells. Given the possibility that pharmacological
treatments may modulate DNA methylation in CD4+ T
cells, we first stratified patients depending on whether
they were taking immunosuppressors or vasodilators at
the time of sample collection. No significant DMPs
(FDR > 0.05) were identified when comparing treated
and untreated patients. Second, we evaluated whether
treatment may be a confounding variable in identified
SSc-associated DMPs, and observed no significant asso-
ciations (Wilcoxon p value > 0.05) between treatment
and DNA methylation (Additional file 3: Fig. S1C).
Hence, DMPs identified were specifically associated with
SSc disease. SSc patients were then stratified as diffuse
(dcSSc), limited (lcSSc), or sine scleroderma (ssSSc),
with the latter having no skin fibrosis. Early scleroderma
(eSSc) was excluded from the analysis due to the very
limited number of patients in this group. We analyzed
aberrant DNA methylation of SSc subgroups and ob-
served that many of the alterations (35%) were shared
between at least two of the three subgroups (Additional
file 3: Fig. S1C). Furthermore, subgroup-specific DMPs
also displayed some degree of aberrancy in other SSc
subgroups that did not reach statistical significance
(Additional file 3: Fig. S1D), suggesting that the majority
of alterations are shared among groups. Nevertheless,
the lack of significant differences observed between SSc
subtypes may be due to a lack of statistical power as a
result of the small number of patient samples in each
group. Altogether, despite the small cohort of patients,
our results suggest that aberrant DNA methylation of
CD4+ T cells may be a common hallmark of all sub-
groups of SSc.
Differentially methylated regions enriched in NF-κB
signaling pathway
Although the identification of single DMPs can hint at
possible alterations in the genomic landscape, differen-
tially methylated regions (DMRs) may give functional
relevance to DNA methylation, as DMRs have been de-
scribed to correlate well with transcription, chromatin
features, and phenotypic outcomes [56, 57]. Accordingly,
we identified 1082 significant DMRs, in which 212 and
870 DMRs were hypo- and hypermethylated, respect-
ively. More than 25% of DMRs were found to be situated
in promoters of the nearest gene, and the same
(See figure on previous page.)
Fig. 1 Aberrant DNA methylation in inflammatory loci of SSc CD4+ T cells. a Scheme depicting workflow including PBMC isolation, CD4+ T cell
positive sorting, and DNA and RNA extraction. b Gating strategy to eliminate cell debris, doublets, and the isolation of CD4-APC+ T lymphocytes
by side scatter. c Heatmap of differential methylated CpGs (DMPs), in which 7837 CpGs were hypermethylated (log2FC > 0, FDR < 0.05) and 1275
CpGs were hypomethylated (log2FC < 0, FDR < 0.05) in SSc patients (n = 48) compared to healthy control (n = 16). d t-SNE clustering of SSc and
HD samples based on all identified DMPs. e Gene ontology of hyper- and hypomethylated DMPs, analyzed utilizing the GREAT online tool
(http://great.stanford.edu/), in which CpGs annotated in the EPIC array were used as background. f HOMER motif enrichment of hyper- and
hypomethylated CpGs, utilizing CpGs annotated in the EPIC array as background. A window of ± 250 bp centering around each DMP was
applied. g Enrichment of DNase I hypersensitivity, H3K9me3, H3K4me3, H3K4me1, H3K36me3, H3K27me3, and H3K27ac ChIP-seq data, obtained
from the BLUEPRINT portal, in hyper- and hypomethylated DMPs. Highlighted circles represent statistically significant comparisons (p value < 0.01
and odds ratio > 1) compared to background. h Overlap between DMPs and differentially variable CpGs (DVPs), identified utilizing the iEVORA
algorithm (left), and graphical representation of variance of identified DVPs in HD and SSc
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proportion of DMRs were found more than 50 kb from
TSS (Additional file 5: Fig. S2A). Many of the identified
DMRs were mapped to such relevant genes as
COLEC11, GSTM1, HLA-C, and IL15RA (Fig. 2a). Gene
ontology analyses revealed that hypermethylated DMRs
were significantly enriched in various categories relevant
to immune functions, IL-10 secretion, Th2 cytokine pro-
duction and differentiation, NLRP3 inflammasome
complex, and negative regulation of NF-κB signaling
(Fig. 2b; Additional file 6. Table S4). On the other hand,
hypomethylated DMRs were enriched in peptide antigen
binding, MHC protein complex, IL-1 binding, and
chemotaxis (Fig. 2b; Additional file 6: Table S4). Further-
more, both hyper- and hypomethylated DMRs over-
lapped significantly with H3K4me1 histone mark and
DNase I hypersentivity regions, indicating the presence
Fig. 2 Differentially methylated regions (DMRs) enrich in inflammatory loci and pro-inflammatory transcription factors. a Graphical representation
of beta values of identified DMRs, utilizing bumphunter tool, mapped to relevant genes, including COLEC11, GSTM1, HLA-C, and IL15RA. Identified
DMRs are highlighted in blue, and CpGs are depicted in black. Lines represent locally estimated scatterplot smoothing, and transparent areas
represent confidence intervals. b GO analysis of hyper- and hypomethylated DMRs utilizing the GREAT online tool. DMRs were mapped to the
nearest gene. c Enrichment of DNase I hypersensitivity, H3K9me3, H3K4me3, H3K4me1, H3K36me3, H3K27me3, and H3K27ac ChIP-seq data,
obtained from the BLUEPRINT portal, in hyper- and hypomethylated DMRs. d Enrichment of TF ChIP-seq peaks in hyper- and hypomethylated
DMRs. ChIP-seq data were downloaded from ReMap database, in which STAT1, RUNX1, NFKB2, MYC, JUN, CTCFL, and CTCF were downloaded as
consolidated ChIP-seq peaks of all available datasets, whereas RELA ChIP-seq peaks were obtained from CD4+ T cells. c, d Background of the
same length as DMRs was generated from EPIC array, in which 1000 resamplings were applied. p values and odds ratios are averages of 1000
permutations. Highlighted circles represent statistically significant comparisons (p value < 0.01 and odds ratio > 1) compared to background
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of enhancers (Fig. 2c). Additionally, hypermethylated
DMRs were enriched in H3K27me3, which, together
with H3K4me1, is a key mark for poised enhancers.
Given the importance of CTCF in mediating long-range
enhancer-DNA interactions and the enrichment of its
motif in both hyper- and hypomethylated DMPs, we
performed overlap between DMRs and CTCF and CTCF
L ChIP-seq peaks obtained from ENCODE. We observed
that hyperDMRs significantly overlapped with both
CTCF and CTCFL binding regions (Fig. 2d). Moreover,
significant overlap was also detected between both
hyper- and hypoDMRs and binding sites of RUNX1,
MYC, and RELA, all of which have important roles in T
cell biology, suggesting that aberrant DNA methylation
in SSc may alter their binding to these regions. Finally,
hypoDMRs were selectively enriched in binding sites of
NFKB2 and JUN (Fig. 2d).
Identification of aberrant gene expression in CD4 T cells
of SSc patients
To characterize gene expression aberrancies in CD4+ T
cells that drive disease pathogenesis of SSc, we per-
formed genome-wide RNA expression analysis and
found that a total 3929 genes displayed differential ex-
pression (differentially expressed genes (DEGs)) between
HD and SSc, of which 1949 and 1980 were down- and
upregulated, respectively (Fig. 3a, b; Additional file 7:
Table S5). To identify the specific pathways that were al-
tered, we performed DAVID gene ontology analysis and
observed that downregulated genes were enriched in
such signaling pathways as T cell receptor, IL-2 produc-
tion, Fc-γ receptor, and interferon-gamma, as well as
genes associated with systemic lupus erythematosus and
viral carcinogenesis (Fig. 3c). Conversely, genes encoding
proteins that propagate signaling pathways such as TNF,
NF-κB, Fc-ε receptor, Wnt, and TLR-9 were upregulated
(Fig. 3c). TF enrichment analysis revealed that upregu-
lated DEGs were driven by such TFs as IRF2, NFKB1,
FOXP1, and SOX10, and downregulated DEGs were reg-
ulated by TFs including EGR1, FOXA1, GATA2/3, and
CTCF (Fig. 3d). Furthermore, the expression of several
transcripts of the HLA cluster were also differentially
expressed in SSc patients (Fig. 3e), which was in accord-
ance with observed aberrant DNA methylation in these
genomic regions. Interestingly, genes encoding several
transcription factors whose motifs were enriched in ab-
errant DMPs were also found to be altered, and these
genes include JUN, FLI1, RUNX1, and CTCF (Fig. 3e).
The expression of other relevant TFs, such as NFKB2,
EGR1, and RELB, were also dysregulated (Fig. 3e). Fol-
lowing deconvolution analyses of CD4 T cell popula-
tions, we observed that there were no significant
differences in percentages of naïve and memory T cells
between SSc and controls (Additional file 5: Fig. S2B).
Evaluating whether vasodilator and immunosupressor
treatments at the time of sample collection may affect
gene expression, we performed limma analyses comparing
treated and untreated patients. We only observed one
gene, RARA, that was differentially expressed (FDR < 0.05)
between patients treated with immunosuppressors and
untreated patients, while no differences in gene expression
were observed in patients on vasodilators. Furthermore,
correlation analyses between treatments and first three
principal components (PCs) of identified DEGs revealed
that neither vasodilators nor immunosuppressors affected
the first two PCs (Additional file 5: Fig. S2C). Vasodilators
correlated significantly with gene expression of PC3; how-
ever, this only accounted for 0.3% of total variance. Hence,
we discarded differences in treatments as confounding
variables to SSc-associated DEGs.
DNA methylation changes establish short- and long-
distance relationships with gene expression in SSc
We then investigated the relationship between DNA
methylation and gene expression deregulation in SSc. TF
binding can be both negatively or positively influenced
by DNA methylation [58, 59]. DNA methylation of gene
TSS associates negatively with gene expression [60],
whereas methylation of CpGs located within gene body
can also associate with active gene expression [61]. To
investigate the potential relationship between DNA
methylation alterations and gene expression in SSc, we
searched for possible meQTLs (methylation-expression
quantitative trait loci). Subsequently, we found 45 differ-
entially methylated CpGs (DMPs) that interacted with
differentially expressed genes (DEGs), in which the CpG
was located near/in the promoter or TSS of the interact-
ing gene (5 kb upstream and 1 kb downstream of TSS),
of which 33 (73.3%) were negative interactions (Add-
itional file 8: Table S6; Fig. 4a). GO analysis of interact-
ing DEGs includes pathways involved in nucleotide-
excision repair, nucleosome assembly, and positive regu-
lation of interferon-beta production (Fig. 4b). Relevant
genes include ADAM20, a member of the ADAM family
of metalloproteases which are involved in T cell re-
sponses [62, 63]; CD274, which, upon binding to its re-
ceptor, mediates changes in T cell metabolism [64]; and
IRF1, a key driver of Th1 cell differentiation [65]
(Fig. 4c).
Given that SSc-associated differentially methylated
CpGs and regions (DMPs and DMRs) were enriched in
H3K4me1, a key histone mark characterizing enhancers,
it is possible that aberrant expression of genes in SSc pa-
tient CD4+ T cells may influence or be influenced by
DNA methylation in distal elements. To interrogate
long-distance correlative interactions, an extended win-
dow of 5Mb between CpG and gene was used to detect
meQTLs followed by extensive multistep filtering
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Fig. 3 (See legend on next page.)
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processes based on the causal inference test [66, 67]
(Fig. 5a). Firstly, DNA methylation and gene expression
correlations between all annotated CpG positions (M)
and genes (E) were searched within a window of 5Mb, in
which a total of 99,525 significant (Pearson p value < 0.01)
CpG-gene interactions were discovered. Secondly, CpG-
gene pairs were then filtered by differential expression and
methylation in SSc patients (Y) compared to healthy con-
trols to yield 17,500 DMP-DEG pairs (5841 unique DMPs
and 3237 unique genes), approximately half (9114 DMP-
DEG pairs) of which were negative correlations. Thirdly,
utilizing previously generated promoter capture Hi-C
(PCHi-C) data of healthy CD4+ T cells [47], we overlapped
promoter-non-promoter interactomes with SSc-associated
DMP-DEG pairs by first overlapping DEGs with annotated
promoters in PCHi-C and then overlapping correlating
DMPs with the interacting non-promoter PCHi-C frag-
ments. Consequently, our analysis yielded 182, 170, and
162 DMP-DEG interactions utilizing datasets from naïve,
non-activated, and activated CD4+ T cells, respectively.
(See figure on previous page.)
Fig. 3 Aberrant gene expression of SSc CD4+ T cells include inflammatory genes and relevant transcription factors. a Differentially expressed
genes (DEGs) comparing RNA expression microarray data of CD4+ T cells isolated from SSc with HD, in which 1949 genes were downregulated
(log2FC < 0, FDR < 0.05) and 1980 genes were upregulated (log2FC > 0, FDR < 0.05). b t-SNE clustering of identified DEGs in HD and SSc CD4 T cell
samples. c GO analysis of down- and upregulated DEGs performed utilizing the DAVID online tool (https://david.ncifcrf.gov/). Bubble size refers to
the size of GO term, and threshold represents the cutoff for statistical significance (p value < 0.05). Relevant GO terms are summarized in tables
before the bubble plots. d TF enrichment analysis, utilizing the DoRothEA tool, of all interrogated genes ordered by normalized enrichment score
(NES) of SSc compared to HD. Dotted red lines represent the cutoffs for statistical significance (NES < − 2 and p value < 0.01, NES > 2 and p value
< 0.01). e Graphical representations of z-scores of genes relevant to T cell biology, including CD3E and IL2RA; transcription factors NFKB2, CTCF,
EGR1, RELB, RUNX1, JUN, and FLI1; and DNA methylcytosine dioxygenase TET3
Fig. 4 Correlation of DNA methylation and gene expression of DMPs situated in gene promoters/TSS. a Percentage of detected short-range interactions
that present either negative or position correlation between DNA methylation and gene expression, in which the DMP is situated in promoter or TSS of
interacting DEG. b GO analysis utilizing the DAVID online tool of the DEGs with short-range interacting DMPs. c Graphical representation of correlation of
DNA methylation and gene expression of DMP-DEG pairs. Red and blue dots represent SSc and HD individuals, respectively
Li et al. Genome Medicine           (2020) 12:81 Page 10 of 17
Following consolidation of the three datasets, we detected a
total of 212 unique DMP-DEG interactions (Add-
itional file 9: Table S7), in which 128 interactions were
shared between all three datasets (Fig. 5b). Furthermore,
these interactions appeared to be specific to CD4+ T cells,
as comparison with PCHi-C data obtained from erythro-
blasts displayed little overlap (Fig. 5a). Additionally, of the
212 DMP-DEG interactions, more than half displayed a
Fig. 5 Long-range interactions identified by promoter capture Hi-C (PCHi-C). a Correlations of possible long-range interactions between DMPs
and DEGs were detected using the MatrixEQTL package by applying a maximum interaction distance of 5 Mb with a Pearson p value cutoff of
0.01. Overview summarizing multistep filtering process based on the causal inference test. Y, SSc phenotype; M, identified DMPs; E, identified
DEGs; S, SSc-associated susceptibility loci. b Heatmap showing the presence (red) or absence (pink) of promoter capture Hi-C (PCHi-C)
interactions of 212 identified DMP-DEGs identified utilizing naïve (nCD4), non-activated (tCD4Non), and activated (tCD4Act) PCHi-C datasets. The
presence or absence of the same interactions was interrogated in erythroblasts (Ery). c Heatmap of log2FC of gene expression and DNA
methylation of the 212 confirmed interacting DMP-DEGs. d Volcano plot of the 212 confirmed DMP-DEG interactions. Correlation coefficient r of
DNA methylation and gene expression values is plotted on the x-axis against −log10(p value) on the y-axis. Genes relevant to T cell biology are
highlighted in red. e Graphical representations of DMP-DEG pairs with significant correlation between DNA methylation and gene expression
(Pearson p value < 0.01). f Overlap between DMP-DEG pairs and PCHi-C data was performed to confirm long-range interactions. Arc plot of long-
distance interactions between DMPs and DEGs as confirmed by PCHi-C, in which confirmed interactions are depicted as purple arcs. HindIII
fragments are depicted in green, and interacting genes and CpGs are highlighted in red
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negative correlation between gene expression and DNA
methylation (Fig. 5c, d). Among these DMP-DEG interac-
tions, aberrantly expressed genes relevant to T cell biology,
such as ANXA6, CCR7, CD274, CD4, CD48, IRAK2, JUND,
and NFKB2, were observed to be part of the same PCHi-C
interactome with CpGs that displayed differential DNA
methylation in SSc patients (Fig. 5d–f).
DMPs and SSc-associated genetic susceptibility loci form
part of the same interactome with DEGs
To fully unravel the relevance of DNA methylation in SSc
pathogenesis, we can hypothesize that SSc-associated genetic
variants may at least partially contribute to aberrant DEG-
interacting CpGs. Hence, we utilized a large GWAS dataset
generated by López-Isac et al. [15], which included 26,679 in-
dividuals that identified 27 SSc-associated risk loci (S) physic-
ally interacting with 43 target genes, as validated by HiChIP
data in CD4+ T cells. We therefore interrogated the pres-
ence of interacting SNPs in association with identified DMPs
and DEGs. We first overlapped the SNP-interacting genomic
regions with identified DEGs and observed that 36 SNP-
interacting genes identified by López-Isac et al. were aber-
rantly expressed in our cohort of SSc (Fig. 6a). Second, of
these 36 DEGs, 5 of them correlated with a SSc-associated
DMP that formed part of the same promoter-non-promoter
interactome, as observed by PCHi-C. Finally, we observed
that 4 of the identified candidate SNP-DEGs further inter-
acted with the gene in which the associated DMP was lo-
cated according to HiChIP data by López-Isac et al. [15]
(Fig. 6b; Additional file 10: Fig. S3A). Specifically, the SSc-
associated susceptibility loci TNIP1 (rs3792783), GSDMB
(rs9303277), IL12RB1 (rs2305743), and CSK (rs1378942)
were possible candidates that interacted with both DMPs,
situated in TNIP1, RARA, LSM4, and MPI, respectively, and
their associated DEGs, namely ANXA6, CCR7, JUND,
and ULK3, respectively (Fig. 6b). Furthermore, we ob-
served that the vicinity of the identified SNPs and
DMPs was particularly enriched in H3K4me1, a clas-
sical mark for enhancers (Additional file 10: Fig. S3B).
Further genotyping of the SSc cohort was performed, and
gene expression and DNA methylation of DEGs and DMPs
were evaluated in patients harboring risk variants compared
to patients without risk variants. We observed a clear cor-
relation between gene expression and DNA methylation
with the presence of risk alleles for ANXA6 and
cg17239269 associated with SNP rs3792783 (TNIP1). For
rs9303277 (GSDMB), only DNA methylation correlated
with risk allele presence, whereas DNA methylation and
gene expression associated with SNPs rs2305743 (IL12RB1)
and rs1378942 (CSK) were not found to correlate well with
the presence of risk variants (Additional file 10: Fig. S3C).
Furthermore, visualizing ChIP-seq data of CTCF and
p65, obtained from the ReMap database, we observed that
the SNP-DMP-DEG interaction regions were extensively
covered by CTCF binding sites. Interestingly, we observed
that p65 binding is predominantly restricted to the pro-
moters/TSS of DEGs ANXA6, CCR7, and JUND. Further-
more, some ChIP-seq peaks were detected near the
interacting CpGs and SNPs, compatible with a poten-
tial role for p65 in the transcriptional regulation of
these genes following correct chromatin looping be-
tween genomic loci (Fig. 6b).
Discussion
In this study, the integrated analysis of DNA methylation,
gene expression, promoter capture Hi-C, and genetic data
potentially unveils novel functional relationships in CD4+
T cells of patients with systemic sclerosis. First, we report
DNA methylation and gene expression alterations in SSc
CD4+ T lymphocytes associated with essential pathways
implicated in T cell differentiation and function. Aberrant
DNA methylation in distinct loci could be directly influen-
cing aberrant gene expression through long-distance in-
teractions that involve CTCF. Finally, we identified four
important SSc-associated susceptibility loci, TNIP1
(rs3792783), GSDMB (rs9303277), IL12RB1 (rs2305743),
and CSK (rs1378942), that form part of the same interac-
tomes with cg17239269-ANXA6, cg19458020-CCR7,
cg10808810-JUND, and cg11062629-ULK3, respectively.
Despite the increasing number of genetic variants as-
sociated with SSc, their functional relevance is still a
challenge. In addition, alongside genetic predisposition,
environmental factors and epigenetic deregulation also
contribute to the pathogenesis of this disease (reviewed
in [68]). Our comprehensive approach has unveiled a
high number of DNA methylation and expression
changes in SSc CD4+ T cells compared to control (9112
DMPs, 1082 DMRs, and 3929 DEGs). The vast majority
of DNA methylation changes were SSc-associated hyper-
methylation. Conversely, only around 10% of changes
corresponded to aberrant hypomethylation, which is per-
haps associated with the increased gene expression of
TET3, as detected by our RNA expression analysis.
TET3 has been previously linked to T cell differenti-
ation, and its deletion resulted in decreased proportions
of progenitor and naïve CD4+ T cells [69]. Therefore,
we cannot discard the possibility that changes in DNA
methylation may be a result of alterations in CD4+ T
cell populations. However, deconvolution analysis
showed no significant differences in the proportions of
memory and naïve T cell populations between SSc and
controls.
Analysis of functional categories of the identified DMPs,
DMRs, and DEGs revealed the enrichment of numerous
relevant pathways, in which many were in accordance to
previous studies, including circadian signaling, Rho pro-
tein signaling, thyroid hormone secretion, T cell activa-
tion, and cytokine-mediated responses [70, 71]; however,
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we were able to identify several novel pathways, including
several cytokine receptor-propagated pathways, MHC
complex assembly, T cell polarization, and NF-κB signal-
ing pathway, among others. Interestingly, several of these
deregulated pathways were enriched in both hyper- and
hypomethylated DMP/DMR datasets. Although we do not
know how aberrant DNA methylation affects the activa-
tion of these pathways, nonetheless, alterations in these
loci may have implications their correct functions. One
such example is the HLA loci, which have been
previously described to associate with SSc disease by
genetic studies [7, 72].
The relationship between DNA methylation and gene
expression is complex, and there are studies describing
DNA methylation as both a cause and a consequence of
gene expression. Furthermore, DNA methylation
Fig. 6 Presence of SSc-associated genetic variants associated with PCHi-C-identified DMP-DEG interactomes. a Multistep filtering process based
on the causal inference test extended from Fig. 5, summarizing the filtering steps adopted to identified four interactomes involving SSc-
associated SNPs, DMPs, and DEGs. Y, SSc phenotype; M, identified DMPs; E, identified DEGs; S, SSc-associated susceptibility loci. b Arcs in green
represent interactions of SSc-associated SNPs with distant genes, as confirmed by López-Isac et al. [15], and arcs in purple represent DMP-DEG
interactions identified and confirmed in this study. HindIII fragments are depicted in green, and interacting genes and CpGs are highlighted in
red. Density plots represent ChIP-seq data of RELA and CTCF. ChIP-seq data were downloaded from ReMap database, in which CTCF were
downloaded as consolidated ChIP-seq peaks of all available datasets, whereas RELA ChIP-seq peaks were obtained from CD4+ T cells
Li et al. Genome Medicine           (2020) 12:81 Page 13 of 17
patterns are highly tissue-specific and are established
during dynamic differentiation events by site-specific re-
modeling at regulatory regions [73]. Nevertheless,
methylation of CpGs located in gene promoter, first
exon, and intron robustly correlates to gene expression
in an inverse manner [74–76]. First, we identified 45
DMPs located within or near the promoter or TSS of
DEGs with statistically significant correlations, with ma-
jority displaying negative correlations. Hence, aberrant
DNA methylation observed in SSc patients may directly
cause aberrant gene expression in CD4+ T cells when
located in/near promoter or TSS regions. Second, gene
expression deregulation of several TFs was observed in
SSc CD4+ T cells, including JUN, CTCF, FLI1, and
RUNX1, whose motifs were enriched in identified DMPs.
Therefore, it is also plausible that aberrant gene expres-
sion of TFs may mediate altered recruitment to their
binding sites, which may consequently shape DNA
methylation patterns at these sites. Several TFs have
been shown to bind unmethylated regions to block de
novo methylation, and one such factor is CTCF, in
which it acts as a boundary element to directly impede
methylation of regulatory regions [77, 78]. Conversely,
other TFs were observed to actively recruit DNA (de)
methylation enzymes. One such example is PU.1, which
has been shown to recruit both TET2 and DNMT3A to
promote DNA demethylation and methylation, respect-
ively [79].
Within the last decade, it has become increasingly
clear the existence of long-range looping interactions be-
tween regulatory elements and promoters, in which only
~ 7% of all looping interactions are with the nearest gene
[80]. These interactions do not only physically exist, but
play essential molecular roles in regulating distant gene
expression in both biological and pathological settings
[47, 81]. Long-range integration of DNA methylation
and gene expression has already been explored in other
disease contexts, in which one study involving a large
cohort of colon cancer patients showed that methylation
of distal CpGs controlled genes at a distance of > 1Mb
[82]. Furthermore, several studies have identified essen-
tial long-range associations between susceptibility loci
with gene expression (GWAS) or with DNA methylation
(EWAS) mediating several autoimmune diseases includ-
ing multiple sclerosis [83], rheumatoid arthritis [84], and
SSc [15]. Our study represents the first to integrate gen-
etic risk with epigenome and transcriptome deregula-
tions within the same interactomes in the context of
autoimmune disease. First, we identified four SSc-DMPs,
cg17239269 (TNIP1), cg19458020 (RARA), cg10808810
(LSM4), and cg11062629 (MPI), whose DNA methyla-
tion correlated with the expression of four distant SSc-
DEGs, ANXA6, CCR7, JUND, and ULK3. Second, these
interactions were identified to exist within the same
interactome in healthy individuals by previously pub-
lished promoter capture Hi-C data from CD4+ T cells
[47]. Third, from the previous study by López-Isac and
colleagues [15], four SSc risk variants, TNIP1
(rs3792783), GSDMB (rs9303277), IL12RB1 (rs2305743),
and CSK (rs1378942), were identified to physically inter-
act with ANXA6, CCR7, JUND, and ULK3, respectively,
as well as with the genes in which the interacting SSc-
DMPs, cg17239269 (TNIP1), cg19458020 (RARA),
cg10808810 (LSM4), and cg11062629 (MPI), respect-
ively, were located. Further genotyping of our SSc cohort
showed that the presence of risk alleles in SNP
rs3792783 (TNIP1) correlated well with differential DNA
methylation and gene expression of associated DMPs
and DEGs, namely ANXA6, which has been described to
be essential to CD4+ T cell proliferation via interleukin-
2 signaling [85]. Other evaluated risk variants were not
observed to correlate with both associated DNA methy-
lation and gene expression. We cannot disregard that
this may be due to the small cohort of patient samples,
coupled with the disparity in numbers of patients versus
healthy controls. Therefore, it is plausible that the num-
ber of patients harboring risk variants was too small to
yield conclusive statistical significance, in which a larger
cohort is required to validate the correlation between
risk variants, DNA methylation, and gene expression.
Nevertheless, although we observed significant changes
in DNA methylation and gene expression, in SSc CD4+
T cells, we cannot conclusively speculate on the effects
these alterations have in regard to chromatin accessibil-
ity and structure without further validation in patients.
However, previous studies do show a direct correlation
between DNA methylation and chromatin states [86–
88]; therefore, it is possible that chromatin structure is
also altered in SSc CD4+ T cells.
One limitation of this study is we cannot accurately
predict whether aberrant DNA methylation is a cause or
consequence of changes in gene expression. However,
given that DMPs were found to enrich in CTCF binding
motifs, which may be a consequence of aberrant upregu-
lation of the CTCF gene in SSc CD4+ T cells, and the
importance of CTCF in enabling chromatin loop forma-
tion [89], it is therefore possible that aberrant DNA
methylation deregulates CTCF recruitment, which has
been previously described to be DNA methylation-
dependent [90], in turn affecting long-range interactions
with distant genes to alter their expression. However,
further validation in SSc CD4+ T cells would be re-
quired to fully determine the role of the formation of
these interactomes in mediating SSc disease risk.
Collectively, our results showed the occurrence of
widespread DNA methylation and expression alterations
in SSc CD4+ T cells, which at least are in part deter-
mined through long-distance interactions. Additionally,
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we have detected the presence of four causal risk vari-
ants which may be associated with aberrant DNA
methylation and gene expression. Although we do not
directly validate these interactions in our SSc cohort, in-
tegrative analyses of GWAS and PCHi-C suggest that
these SNPs, DEGs, and DMPs form part of the same
interactomes.
Conclusions
In the present study, we have shown that CD4+ T
cells from SSc patients display widespread changes in
their methylomes and transcriptomes in relation to
healthy controls. Many of the changes enrich in func-
tional categories associated with T cell biology and
inflammation. We observed significant correlations
between DNA methylation and gene expression alter-
ations. In fact, using promoter capture Hi-C data, we
observed that numerous DMP-DEG pairs form inter-
actomes in healthy CD4+ T cells. Finally, we show
that these alterations appear to be associated with the
presence of SSc-susceptibility loci that form part of
the same interactomes with DMP-DEG pairs. In
summary, our study established a novel link between
genetic susceptibility in SSc and DNA methylation-
associated transcriptional changes in CD4+ T cells,
providing a perspective on the relationship between
genetic and epigenetic factors contributing to the
aberrant behavior of CD4+ T cells in SSc.
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